

COVID-19 pandemic: IFAPP recommendations to its members

To our members,

IFAPP is aware of the need for a coordinated use of resources including our affiliated biomedical professionals to combat COVID-19, both in terms of the scientific effort to produce vaccines and treatments, and in their experience in clinical settings and patient care.

At the current time we understand those employed by pharmaceutical companies or contracted by them, especially those involved in on-going research and clinical trials, might be valuable in this coordinated fight.

In a joint initiative with the Faculty of Pharmaceutical Medicine and the IFAPP Academy, at the current time IFAPP is recommending that:

- All biomedical professionals employed by pharmaceutical companies and regulatory bodies must follow their organizational guidance and ensure that patient safety is not compromised;
- Pharmaceutical physicians should use their best judgement as to where their own skills and knowledge are best used. This may be in a scientific capacity within their respective organizations or by returning to clinical practice;
- Depending on their personal circumstances, pharmaceutical physicians who have relinquished their licence to practice or have retired and de-registered in the last three years can consider pursuing voluntary temporary registration and join the global efforts. IFAPP urges all our members to consider how they might best support the national and international effort to combat COVID-19;

- If individual members and national member associations feel they need further guidance, advice and support, please contact us at secretariat@ifapp.org

March 23, 2020

The IFAPP Board of Directors

Kyoko Imamura, MD, PhD (President)

Honorio Silva, MD (Past President)

Marco Romano, MD (President-Elect)

Kotone Matsuyama, PhD (Secretary)

Brigitte Franke-Bray, MD (Treasurer)

Domenico Criscuolo, MD, PhD

Sandor Kerpel-Fronius, MD, PhD

Gustavo Kesselring, MD

Peter Stonier, MD, PhD